Novartis Presents Remibrutinib Phase III Data Across Three Indications at EAACI Congress 2026

Scaling a BTK inhibitor across chronic spontaneous urticaria, chronic inducible urticaria, and IgE-mediated food allergy simultaneously places measurable pressure on CMC planning and process validation, and Novartis is now surfacing the clinical data that will drive those downstream manufacturing decisions. The company will present findings from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, with remibrutinib (Rhapsido®) at the centre of the programme.

Two late-breaking oral presentations anchor the schedule. The Phase III RemIND trial, described as the largest study conducted in chronic inducible urticaria, will be presented on June 12, followed immediately by randomised withdrawal data from the Phase IIIb REMIXED extension study in chronic spontaneous urticaria. Together, these datasets will inform the benefit-risk profile regulators and QA teams will scrutinise as remibrutinib moves toward potential label expansions across multiple indications.

The indication breadth carries direct implications for production planning. Remibrutinib is a small molecule, but multi-indication development programmes typically require parallel dose-ranging work, a point underscored by the inclusion of a Phase II dose-response analysis in adults with IgE-mediated peanut allergy. Divergent therapeutic doses across indications can complicate batch release specifications, comparability protocols, and the process validation packages required under 21 CFR Part 211 and ICH Q10 quality system frameworks.

Additional abstracts address B-cell biomarker correlations with clinical response in CSU, real-world evidence from the REASSERT non-interventional study, and findings from the CURE Registry on unmet needs in treatment escalation. Two China-specific datasets from the Urticaria Voices programme extend the evidence base into a geography where regulatory submissions will require locally relevant safety and effectiveness data.

For regulatory affairs leads tracking the remibrutinib dossier, the EAACI presentations will generate reference data sets that are likely to appear in future supplemental NDA or MAA filings; the RemIND Phase III results and the REMIXED extension data are the submissions most proximate to a near-term regulatory action.

The completeness of the dose-response characterisation across indications, particularly the peanut allergy Phase II analysis, will be a key checkpoint before any multi-indication process validation strategy can be finalised.

Source: Novartis via GlobeNewswire, 8 June 2026.